SEC-sourced researchBeta
SYRE
Spyre Therapeutics, Inc.
Company comparison ↗
Data passport
- CIK
- 0001636282
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Oct 7, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 886,000.0000 | Feb 19, 2026 |
| December 2024 | 0.0000 | Feb 19, 2026 |
| December 2025 | 0.0000 | Feb 19, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 0.0000 | -155,203,000.0000 | -169,252,000.0000 | 777,781,000.0000 | 62,545,000.0000 | Feb 19, 2026 |
| December 2024 | 0.0000 | -208,018,000.0000 | -157,410,000.0000 | 608,484,000.0000 | 90,680,000.0000 | Feb 19, 2026 |
| December 2023 | 886,000.0000 | -338,790,000.0000 | -99,910,000.0000 | — | — | Feb 19, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $0 | December 2025 | Feb 19, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $0 | December 2024 | Feb 19, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$155.2M | December 2025 | Feb 19, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$169.25M | December 2025 | Feb 19, 2026 | 10-K |
| Total assetsAssets | $777.78M | December 2025 | Feb 19, 2026 | 10-K |
| Total liabilitiesLiabilities | $62.55M | December 2025 | Feb 19, 2026 | 10-K |
New filings
- 8-KSYRE · Spyre Therapeutics, Inc.Oct 7, 2026 · Current event
- 424B5SYRE · Spyre Therapeutics, Inc.Oct 6, 2026 · Other
- 424B5SYRE · Spyre Therapeutics, Inc.Oct 5, 2026 · Other
- 4SYRE · Spyre Therapeutics, Inc.Oct 2, 2026 · Other
- 4SYRE · Spyre Therapeutics, Inc.Oct 2, 2026 · Other
- 4SYRE · Spyre Therapeutics, Inc.Oct 2, 2026 · Other
- 144SYRE · Spyre Therapeutics, Inc.Oct 1, 2026 · Other
- 144SYRE · Spyre Therapeutics, Inc.Oct 1, 2026 · Other
- SCHEDULE 13GSYRE · Spyre Therapeutics, Inc.Oct 1, 2026 · Other
- 144SYRE · Spyre Therapeutics, Inc.Sep 30, 2026 · Other
- 8-KSYRE · Spyre Therapeutics, Inc.Sep 8, 2026 · Current event
- 4SYRE · Spyre Therapeutics, Inc.Sep 3, 2026 · Other
- 4SYRE · Spyre Therapeutics, Inc.Sep 3, 2026 · Other
- 4SYRE · Spyre Therapeutics, Inc.Sep 3, 2026 · Other
- 144SYRE · Spyre Therapeutics, Inc.Sep 1, 2026 · Other
- 10-KSYRE · SPYRE THERAPEUTICS, INC.Feb 19, 2026 · Annual